Dermatologic infections in cancer patients treated with checkpoint inhibitors.
J Am Acad Dermatol
; 85(6): 1528-1536, 2021 12.
Article
em En
| MEDLINE
| ID: mdl-33744355
ABSTRACT
BACKGROUND:
The incidence of dermatologic infections in patients receiving checkpoint inhibitors (CPIs) has not been systematically described.OBJECTIVE:
Identify the incidence of dermatologic infections in patients who received CPIs.METHODS:
Retrospective review of dermatologic infections in patients who received CPIs between 2005 and 2020 and were evaluated by dermatologists at Memorial Sloan Kettering Cancer Center.RESULTS:
Of 2061 patients in the study, 1292 were actively receiving CPIs (≤ 90 days since the last dose) and 769 had previously been on CPIs (> 90 days since the last dose). The dermatologic infection rate was significantly higher in patients with active CPI treatment (17.5%) than in patients not actively being treated (8.2%; P < .0001). In patients on CPIs, 82 (36.2%), 78 (34.5%), and 48 (21.2%) had bacterial, fungal, and viral infections, respectively, and 18 (8.0%) had polymicrobial infections. Anti-cytotoxic T-lymphocyte-associated antigen-4 monotherapy was associated with the highest risk of infection (hazard ratio, 2.93; 95% confidence interval, 1.87 to 4.60; P < .001).LIMITATIONS:
Retrospective design and sample limited to patients referred to dermatology.CONCLUSIONS:
Patients actively receiving CPIs are more susceptible to dermatologic infections, with anti-cytotoxic T-lymphocyte-associated antigen-4 monotherapy carrying the highest risk, suggesting that the index of suspicion for infections should be increased in these patients to minimize morbidity and optimize care.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias
Tipo de estudo:
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
J Am Acad Dermatol
Ano de publicação:
2021
Tipo de documento:
Article